Lu-177 Targeted molecular radiotherapy
Lutetium-177 (Lu-177) is being widely used as a promising radionuclide for targeted therapy and is emerging as a game-changing theranostic isotope for the treatment of neuroendocrine tumors, metastatic castration-resistant prostate cancer (mCRPC) along with its development for new carrier molecules that can provide selective targeting for tumor sites.
Numerous clinical trials have demonstrated that Lu 177 treatments are effective for improving the quality of life and progression-free survival in patients with these indications.
Isotopia Ltd is the only company that supplies LU-177 both no-carrier-added (NCA) and carrier-added (CA).
We provide:
- Global production and supply by demand of Lu-177 for any quantity required.
- A stable, reliable, and always on time supply, along with guidance and support whenever needed.
- Production of Lu 177 that fully complies with cGMP regulations (and conforms to the European Pharmacopeia’s monograph).
Global Reliability: Lu-177 Supply Across Three Strategic Locations
We ensure a robust and sustainable supply of Lutetium-177 through our production sites in Israel, North America, and our new facility at Seibersdorf Laboratories in Austria, which holds full marketing authorization.
This comprehensive network guarantees uninterrupted weekly deliveries of Lutetium n.c.a., and our planned expansion into Asia will further strengthen our global presence.
Operating across three continents, we are dedicated to meeting the diverse needs of our customers by providing exceptional solutions and consistent support.
By partnering closely with industry leaders and healthcare providers, we are at the forefront of advancing nuclear medicine, setting new benchmarks in quality and care.
I want more details please
